PXL770: dosing from clinical trials
> Updated:
Human schedule
PXL770 is an oral direct AMPK activator; in studies it was taken as capsules/tablets. Below is a generalization of the Phase 2a (STAMP-NAFLD) regimens.
This is a concise reference to regimens described for adults; it is not an individual prescription.
Unlike the peptides on this site, PXL770 is taken orally, so the dosing question here is less about injection frequency and more about splitting the same daily amount into one dose or two.
| Period / condition | Dose | Escalation |
|---|---|---|
| Lower regimen | 250 mg once daily, oral | Starting dose |
| Split regimen | 250 mg twice daily (500 mg/day) | Increase if needed |
| Main studied regimen | 500 mg once daily | Maximum in this schedule |
Practical dosing and effect details
The STAMP-NAFLD trial (Cusi and colleagues, The Lancet Gastroenterology & Hepatology, 2021) compared three regimens: 250 mg once daily, 250 mg twice daily, and 500 mg once daily, all oral, over 12 weeks.
Across the full study population, PXL770 did not produce a statistically significant reduction in liver fat content versus placebo. But in the subgroup with coexisting type 2 diabetes (roughly 40–47% of each arm), the effect on liver measures and glycemic control was noticeably stronger than in the overall sample.
So instead of a simple higher-dose-stronger-effect pattern, the outcome here tracked which subgroup was being measured more than the milligram amount or the split-versus-single regimen itself. Researchers did not treat 250 mg twice daily as equivalent to 500 mg once daily even though the daily total is the same: for an oral drug, dosing frequency changes peak blood concentration in a way that an equal weekly total does not for a short-lived injected peptide.
This is reference information drawn from a published trial, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.